LBA1 Efficacy and Safety of Adjuvant Alectinib Vs Platinum-Based Chemotherapy (CT) in Patients (pts) from Asia with Resected, Early-Stage ALK+ Non-Small Cell Lung Cancer (NSCLC): A Sub Analysis of ALINA

J. S. Ahn,Y-L. Wu,R. Dziadziuszko,F. Barlesi,M. Nishio,D. H. Lee,J-S. Lee,W-Z. Zhong,H. Horinouchi,W. Mao,S. Lu,Q. Wang,C-T. Yang,K. Korphaisarn,T. Xu,L. Bu,A. Scalori,P. Petric,K. Redhead,B. Solomon
DOI: https://doi.org/10.1016/j.annonc.2023.10.547
IF: 51.769
2023-01-01
Annals of Oncology
Abstract:Adjuvant CT yields modest survival benefits in pts with resected early-stage ALK+ NSCLC. Alectinib has shown efficacy in pts with advanced ALK+ NSCLC. ALINA (NCT03456076) is a global, open-label, phase 3, randomized trial of adjuvant alectinib vs CT in pts with resected stage IB–IIIA, ALK+ NSCLC. In the global ALINA population, a significant disease-free survival (DFS) benefit was seen with alectinib vs CT (hazard ratio [HR] in the stage IB–IIIA population [n=257]: 0.24, 95% CI 0.13–0.43, p<0.0001). This subgroup analysis focuses on the pts enrolled in South Korea, mainland China, Japan, Taiwan and Thailand.
What problem does this paper attempt to address?